State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 3,010,531 shares of Vanda Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 3,010,531 shares of Vanda Pharmaceuticals Inc. common stock.
  • Percent of class: The filing states the shares represent 5% of the class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 2,938,155 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared power to dispose of 3,010,531 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company as the relevant investment adviser subsidiaries.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026, according to the document.

State Street Discloses Passive 5% Position in Vanda Pharmaceuticals

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Vanda Pharmaceuticals Inc. (CUSIP 921659108). Vanda Pharmaceuticals is headquartered at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, D.C. 20037, according to the filing. The triggering event was dated September 30, 2026, and the statement was signed on November 9, 2026, by Alok Maheshwary, Senior Vice President of State Street Corporation.

According to the filing, State Street holds an aggregate of 3,010,531 shares beneficially owned, representing 5% of the class of common stock. The company reported zero sole voting power and zero sole dispositive power. Shared voting power was listed as 2,938,155 shares, while shared dispositive power covered the full 3,010,531 shares. The filing identifies State Street's type of reporting person as "HC," denoting a parent holding company or control person.

Four investment adviser subsidiaries are identified in Item 7 as having acquired the securities: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; and State Street Global Advisors Trust Company. The filing certifies, in the words of the document, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 5% beneficial ownership stake of 3,010,531 shares of Vanda Pharmaceuticals Inc. common stock via Schedule 13G, with the position held through four investment adviser subsidiaries and carrying no sole voting or dispositive power.